News
EU to provide incentives for “orphan” drugs
BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7245.1294 (Published 13 May 2000) Cite this as: BMJ 2000;320:1294- Rory Watson
- Brussels
The European Union has introduced new legislation designed to encourage pharmaceutical companies to develop treatments for “orphan” (rare)diseases that affect fewer than five people in every 10000 within the 15 member bloc.
Since the beginning of this month companies have been able to apply to the London based European Agency for the Evaluation of Medicinal Products …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.